Why Malaysian Medical Device Registrations Fail: Six Rejection Causes and Remedies

1. Key takeaways

MDA/GL/MD-01 is the official starting point for understanding why Malaysian medical device applications fail. The third edition of the guideline, issued in March 2019, added specific treatment of two distinct outcomes: Return of Application and Refusal to Register. The distinction matters because the consequences differ, and because each outcome points to a different remedy. Beyond the guideline text, rejection experience clusters into six recurring causes that cover classification, grouping, technical documentation, quality system and post-market evidence, labelling and claims, and procedural handling. Most of these are documentary failures identified before any substantive technical judgement is reached, which is why a structured pre-submission discipline removes a large share of the risk.

• Classification error, where the class is not argued against the First Schedule or conflicts with the CAB view.
• Grouping non-compliance, where the three rules of same name, same manufacturer and same intended use are not satisfied.
• Technical documentation gaps, including missing CSDT elements and test reports that do not match the claims.
• Insufficient QMS or PMS evidence, where GDPMD or PMS records cannot support the assessment.
• Labelling or claims violations, typically claims that extend beyond the registered intended use.
• Procedural failures, such as late payment or a late response to a deficiency, which is treated as a withdrawal.
• Refusal does not remove the right to reapply; a corrected submission can be filed with fees calculated again.

2. Legal basis

The procedural framework sits in MDA/GL/MD-01, whose third edition of March 2019 introduced the Return of Application and Refusal to Register explanations. The underlying statutory provisions are in Act 737: section 6(4) and section 6(5) govern the handling of applications and the consequence of failing to respond within the allowed period, while section 7 establishes the registration requirement itself. Section 6(5) provides that a deficiency response submitted after the deadline is treated as a withdrawal, but the provision does not affect the applicant’s right to submit a fresh application. Where the dispute concerns classification rather than documentation, section 3(2) allows the matter to be referred to MDA for a ruling. The classification rules themselves are in the First Schedule to the Medical Device Regulations 2012, and the grouping rules are in the Second Schedule. Claims compliance is addressed in MDA/GD-0032, which is the reference point when a rejection turns on promotional or labelling language rather than on technical evidence. Read together, these provisions create a sequence in which documentation is examined first, deadlines are enforced strictly, and only the classification question has a dedicated referral mechanism. The guideline does not create a separate appeal track for the remaining causes; the remedy is a corrected submission, which is why the practical value of the document lies in predicting the outcome rather than contesting it.

3. Expert insights

The six causes are not equally weighted in practice. Classification and grouping errors are structurally the most damaging, because they invalidate the frame within which every other document is read. A file that argues the wrong class, or groups products that do not share a name, a manufacturer and an intended use, cannot be repaired by improving the technical documentation; the submission has to be rebuilt. Reviewers detect these errors quickly, since the classification rationale and the grouping statement appear early in the dossier and can be tested against the schedules without any technical analysis.

Technical documentation gaps and QMS or PMS evidence weaknesses form a second tier. Here the failure is usually one of correspondence rather than absence: a CSDT element is present but does not connect to the claim it is meant to support, or a test report addresses a configuration that differs from the device as submitted, or the GDPMD arrangements and PMS records describe a system that the assessment cannot reconcile with the manufacturing reality. These deficiencies consume rounds because each response requires evidence to be produced or reconciled, and a partial response invites a further round on the same point.

Labelling and claims violations and procedural failures are the most avoidable tier, and they account for a disproportionate share of returned files precisely because they are cheap to prevent. A claim that exceeds the registered intended use is a drafting problem, not an evidentiary one. A missed payment deadline or a late deficiency response is a project management problem. The asymmetry is worth stating plainly: the two tiers that require technical work are hard to eliminate entirely, while the tier that requires discipline can be brought close to zero with a checklist and a calendar. Treating all six causes as equivalent, and therefore allocating attention evenly, is itself a common planning error.

4. Practical recommendations

• Run four cross-checks against the CSDT before submission: claims against evidence, classification against the rules, grouping against the three rules, and labelling against the registered information.
• Where resources allow, obtain a CAB pre-review of the file before formal submission rather than after the first deficiency letter.
• Maintain the rejection list as a negative checklist for internal filing control, with each item signed off before submission.
• Document the classification rationale explicitly against the First Schedule, so that a difference of view can be argued rather than merely asserted.
• Verify that every grouped product genuinely shares the name, manufacturer and intended use, and split the group where any of the three fails.
• Track payment and deficiency deadlines as hard project milestones, since a late response is treated as a withdrawal regardless of file quality.
• Where classification is genuinely contested, consider referring the question to MDA under section 3(2) before building a submission on an uncertain premise.

5. Verification checklist

• □ MDA/GL/MD-01, third edition of March 2019, has been reviewed for the Return of Application and Refusal to Register provisions.
• □ Act 737 sections 6(4), 6(5) and 7 have been checked for deadline consequences and the registration obligation.
• □ The First and Second Schedules to the Medical Device Regulations 2012 have been consulted for classification and grouping.
• □ MDA/GD-0032 has been reviewed where claims or labelling language is in scope.
• □ The negative checklist has been completed and signed for the specific submission, not carried over from a previous file.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com